Allosteric modulators of human A2B adenosine receptor

Background

Among adenosine receptors (ARs) the A_2B subtype exhibits low affinity for the endogenous agonist compared with the A₁, A_2A, and A₃ subtypes and is therefore activated when concentrations of adenosine increase to a large extent following tissue damages (e.g. ischemia, inflammation). For this reason, A_2B AR represents an important pharmacological target.

Methods

We evaluated seven 1-benzyl-3-ketoindole derivatives (7–9) for their ability to act as positive or negative allosteric modulators of human A_2B AR through binding and functional assays using CHO cells expressing human A₁, A_2A, A_2B, and A₃ ARs.

Results

The investigated compounds behaved as specific positive or negative allosteric modulators of human A_2B AR depending on small differences in their structures. The positive allosteric modulators 7a,b and 8a increased agonist efficacy without any effect on agonist potency. The negative allosteric modulators 8b,c and 9a,b reduced agonist potency and efficacy.

Conclusions

A number of 1-benzyl-3-ketoindole derivatives were pharmacologically characterized as selective positive (7a,b) or negative (8c, 9a,b) allosteric modulators of human A_2B AR.

General significance

The 1-benzyl-3-ketoindole derivatives 7–9 acting as positive or negative allosteric modulators of human A_2B AR represent new pharmacological tools useful for the development of therapeutic agents to treat pathological conditions related to an altered functionality of A_2B AR.     

Enhancement of pancreatic lipase inhibitory activity of curcumin by radiolytic transformation

The naturally occurring yellow dietary diarylheptanoid curcumin (1) was converted by γ-ray to two new γ-lactones, curculactones A (2) and B (3), as well as four known transformates, erythro-1-(3-methoxy-4-hydroxy-phenyl)-propan-1,2-diol (4), threo-1-(3-methoxy-4-hydroxy-phenyl)-propan-1,2-diol (5), vanillic acid (6), and vanillin (7). The structures of the two new γ-lactone derivatives were elucidated on the basis of spectroscopic methods. The steroisomeric phenylpropanoids 4 and 5 exhibited significantly enhanced inhibitory activity against pancreatic lipase when compared to parent curcumin.     

Characterization of a Wnt-binding site of the WIF-domain of Wnt inhibitory factor-1

A Wnt-binding site of the WIF-domain of Wnt inhibitory factor-1 was localized by structure-guided arginine-scanning mutagenesis in combination with surface plasmon resonance assays. Our observation that substitution of some residues of WIF resulted in an increased affinity for Wnt5a, but decreased affinity for Wnt3a, suggests that these residues may define the specificity spectrum of WIF for Wnts. These results hold promise for a more specific targeting of Wnt family members with WIF variants in various forms of cancer.

Structured summary of protein interactions

WIFbinds to Wnt7a by surface plasmon resonance (View Interaction)WIFbinds to Wnt4 by surface plasmon resonance (View Interaction)WIF and Wnt3aphysically interact by competition binding (View Interaction 1, 2, 3, 4,5, 6)WIFbinds to Wnt9b by surface plasmon resonance (View Interaction)WIFbinds to Wnt5a by surface plasmon resonance (View Interaction)WIFbinds to Wnt11 by surface plasmon resonance (View Interaction)WIFbinds to Wnt3a by surface plasmon resonance (View Interaction)Wnt-5a and WIFphysically interact by competition binding (View Interaction 1,2, 3, 4, 5, 6)     

Acyl-CoA binding domain containing 3 (ACBD3) recruits the protein phosphatase PPM1L to ER-Golgi membrane contact sites

The metal-dependent protein phosphatase family (PPM) governs a number of signaling pathways. PPM1L, originally identified as a negative regulator of stress-activated protein kinase signaling, was recently shown to be involved in the regulation of ceramide trafficking at ER-Golgi membrane contact sites. Here, we identified acyl-CoA binding domain containing 3 (ACBD3) as an interacting partner of PPM1L. We showed that this association, which recruits PPM1L to ER-Golgi membrane contact sites, is mediated by a GOLD (Golgi dynamics) domain in ACBD3. These results suggested that ACBD3 plays a pivotal role in ceramide transport regulation at the ER-Golgi interface.

Structured summary of protein interactions

ACBD3 and PPM1Lcolocalize by fluorescence microscopy (View interaction)FYCO1physically interacts with PPM1L by pull down (View interaction)SEC14L2physically interacts with PPM1L by pull down (View interaction)ACBD3physically interacts with PPM1L by pull down (View interaction)SEC14L1physically interacts with PPM1L by pull down (View interaction)PPM1Lphysically interacts with ACBD3 by two hybrid (View interaction)     

Tetrameric 1:1 and monomeric 1:3 complexes of silver(I) halides with tri(p-tolyl)-phosphine: A structural and biological study

Silver(I) halides react with tri(p-tolyl)phosphine (tptp, C₂₁H₂₁P) in MeOH/MeCN solutions in 1:1 or 1:3 molar ratios to give complexes of formulae {[AgCl(tptp)]₄} (1) or [AgX(tptp)₃] (X = Cl (2), Br (3), I (4)), respectively. The complexes were characterized by elemental analyses, and FT-IR far-IR, FT-Raman, TG and ¹H, ¹³C, ³¹P NMR spectroscopic techniques. Crystal structures of complexes 2-4 were determined by X-ray diffraction at room temperature (rt). The crystal structure of 1 and 4 was also determined at 100(1) and 140(2) K (lt), respectively. In complex 1 four μ3-Cl ions are bonded with four Ag(I) ions forming a cubane while the coordination sphere of silver(I) ions is completed by one P atom from a terminal tri(p-tolyl)phosphine ligand. In complexes 2-3 one terminal halogen and three P atoms from phosphine ligands form a tetrahedral arrangement around the metal ion. Complexes 1-4 were tested for in vitro cytostatic activity against sarcoma cancer cells (mesenchymal tissue) from the Wistar rat, polycyclic aromatic hydrocarbons (PAH, benzo[a]pyrene) carcinogenesis and against murine leukemia (L1210) and human T-lymphocyte (Molt4/C8 and CEM) cells. The silver(I) complexes 1-4 show strong activity.     

Design and synthesis of 3-(azol-1-yl)phenylpropanes as microbicidal spermicides for prophylactic contraception

We designed a series of 25 3-(azol-1-yl)phenylpropanes which yielded 10 compounds (3, 4, 7, 8, 13, 14, 19, 21, 23, 26) that irreversibly immobilized 100% human sperm at 1% (w/v) concentration in 60 s; 12 compounds (8, 9, 15, 16, 19-21, 23-25, 27, 28) that showed potent microbicidal activity at 12.5-50 μg/mL against Trichomonas vaginalis; and 17 compounds (3-11, 13, 15, 19, 21, 23, 26, 28, 30) that exhibited potent anticandida activity with minimum inhibitory concentration (MIC) of 12.5-50 μg/mL. Almost all the compounds exhibited high level of safety towards normal vaginal flora (Lactobacillus) and human cervical (HeLa) cells in comparison to the marketed spermicide nonoxynol-9 (N-9). All the biological activities were evaluated in vitro. Two compounds (4, 8) with good safety profile exhibited multiple (spermicidal, antitrichomonas and anticandida) activities, warranting further lead optimization for furnishing a prophylactic vaginal contraceptive.     

Rhenium tricarbonyl complexes of 1-benzyl-4-(5-bipyridyl)-1H-1,2,3-triazoles

Copper(I) catalyzed [3+2] cycloaddition reactions between 5-ethynylbipyridine and benzyl, p-methylbenzyl, or m-bromobenzyl azides yields the corresponding 1-benzyl-4-(5-bipyridyl)-1H-1,2,3-triazoles 1-3. Reaction between 1-3 and [NEt₄]₂[Re(CO)₃Br₃] yields the [1-benzyl-4-(5-bipyridyl)-1H-1,2,3-triazole]Re(CO)₃Br complexes 4-6. The Re(CO)₃Br complexes of 5- and 6-ethynylbipyridine complexes (7-8) are prepared in a similar fashion. Cycloaddition reactions between 7 and benzyl azide yields mixtures of 4 and unreacted starting material.     

A monovalent agonist of TrkA tyrosine kinase receptors can be converted into a bivalent antagonist

Background

Receptor tyrosine kinases (RTK) act through dimerization. Previously it was thought that only bivalent ligands could be agonistic, whereas monovalent ligands should be antagonistic. This notion changed after the demonstration that monovalent ligands can be agonistic, including our report of a small molecule monovalent ligand “D3” that is a partial agonist of the NGF receptor TrkA. A bivalent “D3-linker-D3” was expected to increase agonism.

Methods

Dimeric analogs were synthesized and tested in binding, biochemical, and biological assays.

Results

One analog, 1-ss, binds TrkA with higher affinity than D3 and induces or stabilizes receptor dimers. However, 1-ss exhibited antagonistic activity, through two mechanisms. One mechanism is that 1-ss blocks NGF binding, unlike D3 which is non-competitive. Inhibition of NGF binding may be due to the linker of 1-ss filling the inter-receptor space that NGF traverses before docking. In a second mechanism, 1-ss acts as a pure antagonist, inhibiting NGF-independent TrkA activity in cells over-expressing receptors. Inhibition is likely due to 1-ss “freezing” the TrkA dimer in the inactive state.

Conclusions

Dimerization of an RTK can result in antagonism, through two independent mechanisms.

General significance

we report a small molecule monovalent agonist being converted to a bivalent antagonist.     

Structural studies on 1:1 and 2:1 adducts of silver(I) cyanide with alkanediamine ligands

The crystal structures of two 1:1 ligand-silver(I) cyanide complexes, [Ag(CN)(en)] (en = ethane-1,2-diamine) (1) and [Ag(CN)(pn)] (pn = propane-1,2-diamine) (2), and of two 2:1 ligand-silver(I) cyanide compounds, [(AgCN)₂ · tn] (tn = propane-1,3-diamine) (3) and [(AgCN)₂ · bn] (bn = butane-1,4-diamine) (4), were determined from single-crystal X-ray diffraction data, collected at 173 K. In 1 and 2, mononuclear AgCN complexes are formed, in which silver(I) is coordinated by one cyanide and one chelating alkanediamine donor ligand. However, in the dinuclear adducts of 3 and 4, two AgCN units are connected by one alkane-1,n-diamine bridging ligand (n = 3, 4). The resulting molecules of 1-4 are cross-linked via N-H?N hydrogen bonds. Apart from these intermolecular contacts, comparatively short Ag(I)-Ag(I) distances of 3.182(1) Å (in 1), 3.267(1) Å (in 2), 3.023(2) Å (in 3) and 3.050(2) Å (in 4) occur.     

Perfluoroalkylated derivatives of 6-deoxy-6-ethylamino-d-galactose, 1-deoxy-1-methylamino-d-glucitol, and 1-amino-1-deoxy-d-glucitol: syntheses, hemocompatibility, and effect on perfluorocarbon emulsion

N-Polyfluoroalkyl derivatives of 6-deoxy-6-ethylamino-1,2;3,4-di-O-isopropylidene-α-d-galactopyranose (8-10), 1-deoxy-1-methylamino-d-glucitol (13-15), and 1-amino-1-deoxy-d-glucitol (16-18), all possessing perfluoroalkyl segment, were prepared using nucleophilic epoxide ring opening of 2-[(perfluoroalkyl)methyl]oxiranes 1-3. Co-emulsifying properties and hemolytic activity of the new perfluoroalkylated amphiphiles were tested. Both types of the polyol derivatives 8-10 and 13-18 generally displayed good to excellent co-emulsifying properties on testing on perfluorodecalin/Pluronic F-68 microemulsions. Mono-perfluoroalkylated compounds 8-10 and 13-15 displayed high hemolysis, whereas acyclic bis-perfluoroalkylated compounds 16-18 were non-hemolytic even for short perfluorobutyl segment (16). The properties were generally improving with increasing perfluoroalkyl chain length.     

Synthesis, structure, and catalytic ethylene oligomerization of nickel(II) and cobalt(II) complexes with symmetrical and unsymmetrical 2,9-diaryl-1,10-phenanthroline ligands

A series of nickel(II) and cobalt(II) complexes, NiX₂L (X = Cl, Br; 1-6) and CoCl₂L (7-9), with 2,9-diaryl-1,10-phenanthroline ligands (L¹-L³) have been synthesized and characterized by elemental analysis, UV-Vis, IR spectroscopy, and X-ray crystal structural study (for 1, 4-7, 9). The solid-state structures of 1, 5-7 and 9 show four-coordinate, slightly flattened tetrahedral geometry at the Ni(II) or Co(II) center, while 4 is five-coordinated (square-pyramidal), containing a THF molecule as an auxiliary ligand. The title complexes (1-9) display good catalytic activities in ethylene oligomerization when activated with methylaluminoxane (MAO). While the Co(II) precatalysts produce primarily C₄ isomers, the Ni(II) complexes give ethylene dimers and trimers at normal pressure. The activities and yields of linear α-olefins increase with increasing ethylene pressure for the Ni(II) complexes, leading to more high-molar-mass products (C₈-C₁₈). Complex 6 displays the best catalytic activity among the complexes studied (up to 1518 kg/mol[Ni] h at 10 atm).     

Organogallium(III) complexes as apoptosis promoting anticancer agents for head and neck squamous cell carcinoma (HNSCC) cell lines

Organogallium(III) dinuclear (1-9) and tetranuclear (10) complexes present potential therapeutic agents for the treatment of various types of cancer. The antiproliferative activity of 1-10 was evaluated with cell lines of head and neck squamous cell carcinomas, e.g. HN (soft palate), Cal27, Cal33 (tongue) and FaDu (hypopharynx) cell lines. The activity of compound 8 is comparable with that of cisplatin on cell line Cal27 (IC₅₀ 4.6 μM for both compounds). The mode of cell death induced, caspase activity and cell cycle analysis were evaluated for potential hit compounds 3, 5 and 8 Potential hit compounds 3, 5 and 8 were further evaluated for the mode of cell death, caspase activity and cell cycle analysis. Apoptosis induced by compounds 3, 5 and 8 on Cal27 and FaDu cells was confirmed by DNA laddering , as well as acridine orange (AO) and ethidium bromide (EB) double staining. These compounds (3, 5 and 8) induced caspase-independent apoptosis (within 4 h of action) in cell line Cal27. Extrinsic-mediated apoptosis associated with caspase 8 and 3 activation is the main mode of cytotoxicity induced on FaDu cells by compounds 3, 5 and 8. Cell cycle perturbations caused by these compounds are also observed. Our data suggest that compounds 3, 5 and 8 should be studied further for the treatment of head and neck cancer.     

Reactivity of the ligand bis[2-(3,5-dimethyl-1-pyrazolyl)ethyl]ether (L1) with Pd(II) and Pt(II): crystal structure of cis-[PtCl2(L1)]

The coordination chemistry of the ligand bis[2-(3,5-dimethyl-1-pyrazolyl)ethyl]ether (L₁) was tested in front of Pd(II) and Pt(II). Complexes cis-[MCl₂(L₁)] (M=Pd(II) and Pt(II)) were obtained, due to the chelate condition of the ligand and the formation of a stable 10-membered ring. The crystal structure of cis-[PtCl₂(L₁)] was resolved by X-ray diffraction. Treatment of [PdCl₂(L₁)] or [Pd(CH₃CN)₄](BF₄)₂ with AgBF₄ in the presence of L₁ gave the complex [Pd(L₁)₂](BF₄)₂. The initial cis-[PdCl₂(L₁)] was recovered by reacting [Pd(L₁)₂](BF₄)₂ with an excess of NEt₄Cl. Reaction of [Pt(CH₃CN)₄](BF₄)₂ (generated in situ from [PtCl₂(CH₃CN)₂] and AgBF₄ in acetonitrile) with ligand L₁ yields complex [Pt(L₁)₂](BF₄)₂.     

Characterizing the neurite outgrowth inhibitory effect of Mani

Mani (myelin-associated neurite-outgrowth inhibitor) protein is implicated in both axonal guidance and axonal regeneration after central nervous system (CNS) injury. Here, we applied a neurite outgrowth assay, coupled with a siRNA-driven investigation and immunocytochemistry, to unveil Mani’s axonal outgrowth inhibitory effect in embryonic rat cortical primary neurons in vitro. We further demonstrate Mani’s neuronal localization in comparison with a principal subunit, Cdc27, of the anaphase promoting complex (APC). Considering the protein structure of Mani obtained via a series of bio-computational studies, we propose a Cdc27-Mani-APC-related signalling pathway may be involved in CNS axon regeneration.

Structured summary of protein interactions

MANIphysically interacts with DAZAP2 by two hybrid (View interaction)MANIphysically interacts with FAM168A by two hybrid (View interaction)MANIphysically interacts with YPEL2 by two hybrid (View interaction)MANIphysically interacts with TMTC1 by two hybrid (View interaction)     

Study of the coordination behaviour of (3,5-diphenyl-1H-pyrazol-1-yl)ethanol against Pd(II), Zn(II) and Cu(II)

A new easily synthetic route with a 96% yield of ligand 2-(3,5-diphenyl-1H-pyrazol-1-yl)ethanol (L) is obtained. The reactivity of L against Pd(II), Zn(II) and Cu(II) leads to [PdCl₂(L)₂] (1), [ZnCl₂(L)] (2) and [CuCl(L′)]₂ (3) (L′ is the ligand L without alcoholic proton), respectively. According to the different geometries imposed by the metallic centre and the capability of L to present various coordination links, it has been obtained complexes with square planar (1 and 3) or tetrahedral (2) geometry and different nuclearity: monomeric (1 and 2) or dimeric (3). Complete characterisation by analytical and spectroscopic methods, resolution of L and 1-3 by single-crystal X-ray diffraction and magnetic studies for complex 3 are presented.     

Zinc(II) and mercury(II) coordination architectures with two pyridyl/benzimidazol-1-yl-based ligands: Crystal structures and photoluminescent properties

In our efforts to investigate the relationships between the structures of ligands and their complexes, two structurally related ligands, 1-(2-pyridylmethyl)-1H-benzimidazole (L¹) and 1-(4-pyridylmethyl)-1H-benzimidazole (L²), and their four complexes, [Zn(L¹)₂Cl₂] (1), [Hg(L¹)Br₂]_∞ (2), {[Zn(L²)Cl₂](CH₃CN)}_∞ (3) and [Hg(L²)Br₂]₂(CH₃CN)₂ (4) were synthesized and structurally characterized by elemental analyses, IR spectra and single-crystal X-ray diffraction analysis. Structural analyses show that 1 has a mononuclear structure, and 2 and 3 both take 1D structure. While 4 takes a dinuclear structure. 1, 2 and 4 were further linked into higher-dimensional supramolecular networks by weak interactions, such as C-H?Cl and C-H?Br H-bonding, C-H?π, and π?π stacking interactions. The structural differences of 1-4 may be attributed to the difference of the spatial positions of the terminal N donor atoms in the pendant pyridyl groups in L¹ and L², in which the pyridine rings may act as the directing group for coordination and the benzimidazole rings act as the directing group for π?π stacking and C-H?π interactions. The luminescent properties of the corresponding complexes and ligands have been further investigated.     

Mn(II) coordination architectures with mixed ligands of 3-(2-pyridyl)pyrazole and carboxylic acids bearing different secondary coordination donors and pendant skeletons

In our efforts to investigate the factors that affect the formation of coordination architectures, such as secondary coordination donors and pendant skeletons of the carboxylic acid ligands, as well as H-bonding and other weak interactions, two kinds of ligands: (a) 3-(2-pyridyl)pyrazole (L¹) with a non-coordinated N atom as a H-bonding donor, a 2,2′-bipyridyl-like chelating ligand, and (b) four carboxylic ligands with different secondary coordination donors and/or pendant skeletons, 1,4-benzenedicarboxylic acid (H₂L²), 4-sulfobenzoic acid (H₂L³), quinoline-4-carboxylic acid (HL⁴) and fumaric acid (H₂L⁵), have been selected to react with Mn(II) salts, and five new complexes, [Mn(L¹)₂(SO₄)]₂ (1), [Mn(L¹)₂(L²)]_∞ (2), [Mn(L¹)(HL³)₂]_∞ (3), Mn(L¹)₂(L⁴)₂ (4), and [Mn(L¹)₂(L⁵)]_∞ (5), have been obtained and structurally characterized. The structural differences of 1-5 can be attributed to the introduction of the different carboxylic acid ligands (H₂L², H₂L³, HL⁴, and H₂L⁵) with different secondary coordination donors and pendant skeletons, respectively. This result also reveals that the typical H-bonding (i.e. N-H?O and O-H?O) and some other intra- or inter-molecular weak interactions, such as C-H?O weak H-bonding and π?π interactions, often play important roles in the formation of supramolecular aggregates, especially in the aspect of linking the multi-nuclear discrete subunits or low-dimensional entities into high-dimensional supramolecular networks.     

Structure, dynamics and catalytic activity of palladium(II) complexes with imidazole ligands

Several palladium complexes of the type [Pd(im)₂Cl₂], [Pd(im)₃Cl]Cl, and [Pd(im)₄]Cl₂ (im = imidazole 1, 1-methylimidazole 2, 1,2-dimethylimidazole 3, 1-butylimidazole 4, 4a, 1-phenylimidazole 6, 1-phenylimidazoline 7, and 1-methylimidazoline 8) were prepared and structurally characterized. The square planar structure of two new complexes with the composition [Pd(im)₄]Cl₂ (2b, 4b) was confirmed by X-ray analysis. In solution, exchange of imidazole ligands leading to heteroleptic products was evidenced by ESI-MS studies. Two bis-ligated complexes, bearing 1-methylimidazole (2a) and 1-propoxymethylimidazole (5) ligands, were obtained in the reaction of palladium with imidazoles formed by deprotection of one nitrogen atom in the respective imidazolium halides. Catalytic Suzuki-Miyaura reactions were carried out using the obtained palladium complexes in isopropanol-water solution. High yields of the cross-coupling products were obtained at 40 and 60 °C when 2-bromotoluene, 4-bromotoluene, and 4-bromoanizole were used as substrates.     

Genome-wide biochemical analysis of Arabidopsis protein phosphatase using a wheat cell-free system

Plant genome possesses over 100 protein phosphatase (PPase) genes that are key regulators of signal transduction via phosphorylation/dephosphorylation event. Here we report a comprehensive functional analysis of protein serine/threonine, dual-specificity and tyrosine phosphatases using recombinant PPases produced by wheat cell-free protein synthesis system. Eighty-two recombinant PPases were successfully produced using Arabidopsis full-length cDNA as templates. In vitro PPase assay was performed using phosphorylated myelin basic protein as substrate. Among the AtPPases examined, 26 serine/threonine, three dual-specificity and one tyrosine PPases exhibited catalytic activity, including 20 serine/threonine and one dual-specificity PPases that showed in vitro activities for the first time. Our study demonstrates genome-wide biochemical analysis of AtPPases using wheat cell-free system, and provides new information and insights on enzyme activities.

Structured summary of protein interactions

PTP1dephosphorylatesMBP by phosphatase assay (View interaction).AtPP2CdephosphorylatesMBP by phosphatase assay (View interaction).POLTEdephosphorylatesMBP by phosphatase assay (View interaction).TOPP8dephosphorylatesMBP by phosphatase assay (View interaction).HAB1dephosphorylatesMBP by phosphatase assay (View interaction).ABI2dephosphorylatesMBP by phosphatase assay (View interaction).At1g34750dephosphorylatesMBP by phosphatase assay (View interaction).At1g43900dephosphorylatesMBP by phosphatase assay (View interaction).At3g15260dephosphorylatesMBP by phosphatase assay (View interaction).At5g53140dephosphorylatesMBP by phosphatase assay (View interaction).At1g18030dephosphorylatesMBP by phosphatase assay (View interaction).At3g06270dephosphorylatesMBP by phosphatase assay (View interaction).At2g25070dephosphorylatesMBP by phosphatase assay (View interaction).At3g02750dephosphorylatesMBP by phosphatase assay (View interaction).At5g10740dephosphorylatesMBP by phosphatase assay (View interaction).at4g26080dephosphorylatesMBP by phosphatase assay (View interaction).At4g28400dephosphorylatesMBP by phosphatase assay (View interaction).At5g06750dephosphorylatesMBP by phosphatase assay (View interaction).At4g31860dephosphorylatesMBP by phosphatase assay (View interaction).At3g17250dephosphorylatesMBP by phosphatase assay (View interaction).At4g38520dephosphorylatesMBP by phosphatase assay (View interaction).At3g05640dephosphorylatesMBP by phosphatase assay (View interaction).At5g66080dephosphorylatesMBP by phosphatase assay (View interaction).At1g79630dephosphorylatesMBP by phosphatase assay (View interaction).At2g30170dephosphorylatesMBP by phosphatase assay (View interaction).At5g24940dephosphorylatesMBP by phosphatase assay (View interaction).     

Aliphatic and aromatic C-H activation of benzo[h]quinolines by Rh(I). Unique precursor dependent formation of mono-, di- and trinuclear complexes

Treatment of 7,8-benzo[h]quinoline (bhq-H, 1) and 10-methyl benzo[h]quinoline (bhq-Me, 3) with [Rh(C₂H₄)₂(THF)₂][BF₄] resulted in double C-H activation of aliphatic and aromatic C-H bonds, yielding the Rh(III) complexes 4 and 5, respectively. The structures of 4 and 5 were revealed by X-ray diffraction. The reaction of 1 with two other slightly different rhodium precursors, [Rh(olefin)_n(THF)₂][BF₄] (COE (n = 2), COD (n = 1)), led to completely different products, a dinuclear complex 7 and a trinuclear complex 6, respectively, which were characterized by X-ray diffraction. Complex 6 exhibits a rare linear Rh-Rh-Rh structure. Utilizing excess of 1 with [Rh(COD)(THF)₂][BF₄] led to the formation of a new product 8 with no C-H bond activation taking place. Additional C-H activation products of 1, cationic and neutral, in the presence of PⁱPr₃ (9a, 9b and 10) are also presented.